Biotech Stocks

Stemline Therapeutics (STML) Gets One Step Closer to EMA Approval; Analyst Weighs in With U.S. Angle

Stemline Therapeutics (STML) announced the European Medicines Agency (EMA) is granting accelerated assessment for the company’s marketing authorization for oral treatment, Elzonris. The …

Cowen Analyst Bullish On Vertex (VRTX) Stock After Company Releases Favorable Data

Biopharmaceutical Vertex’ (VRTX) is working on a trial called Phase III VX-659 and Cowen analyst Phil Nadeau calls some recently released data “Good …

Why Does this Analyst Slash His Price Target in Half — Right Before Launch of Paratek Pharmaceuticals’ (PRTK) Drug NUZYRA?

Paratek Pharmaceuticals (PRTK) is preparing to launch its drug NUZYRA, following FDA approval granted on October 2nd. The medication treats both community-acquired bacterial …

Should You Pull the Trigger on Nektar (NKTR) Stock Following Updated Melanoma Data?

Nektar Therapeutics (NKTR) presented some updated results on Friday, November 9th from the melanoma expansion cohort of Phase II from PIVOT-02 study. The cancer-focused …

Akers Biosciences (AKER) Stock Soars on Back of Potential Cannabis Collaboration

On a day like today, when the entire stock market is under pressure, you must have done something right to see your stock …

Tilray (TLRY) Stock Is Headed for a Bumpy Ride, But Upside Remains Long-Term

Canadians from coast to coast toked up in celebration of marijuana’s legalization just about a month from ago when it was legalized on …

Amarin’s (AMRN) Recent Heart Data is Just the Beginning… Not the End for the Stock

Amarin Corporation (AMRN) released a firecracker presentation Saturday at Chicago’s American Heart Association conference and investors can’t seem to stop talking about it. …

Tilray (TLRY) Is a Winner, but the Stock’s Valuation Is Pretty Full, Says Analyst

Let’s take a look at the green. Cannabis company Tilray (TLRY) reported third-quarter earnings that fit in line with the company’s outlook for …